Overview

An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

Status:
Completed
Trial end date:
2016-09-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical efficacy of VTP-38543 administered as a cream, twice-daily, for 28 days in otherwise healthy adult male and female participants with mild to moderate atopic dermatitis.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vitae Pharmaceuticals, Inc.
Treatments:
Ether